{
    "clinical_study": {
        "@rank": "47019", 
        "acronym": "ATHENA II", 
        "arm_group": [
            {
                "arm_group_label": "Adipose-Derived Regenerative Cells (ADRCs) - Celution System", 
                "arm_group_type": "Experimental", 
                "description": "Adipose-Derived Regenerative Cells (ADRCs) processed by the Celution System:\n0.8 x 10^6 cells/kg body weight (not to exceed 80.0 x 10^6 cells)\nDelivered via the MYOSTAR\u2122 Injection Catheter in 15 intramyocardial injections"
            }, 
            {
                "arm_group_label": "Placebo - Physiological Solution", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo - Physiological Solution\nInactive substance (Lactated Ringers + autologous blood)\nDelivered via the MYOSTAR\u2122 Injection Catheter in 15 intramyocardial injections"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a prospective, randomized, placebo-controlled, double blind safety and  efficacy\n      clinical trial."
        }, 
        "brief_title": "Safety & Efficacy of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia (ATHENA II)", 
        "completion_date": {
            "#text": "December 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Myocardial Ischemia", 
        "condition_browse": {
            "mesh_term": [
                "Myocardial Ischemia", 
                "Coronary Artery Disease", 
                "Heart Diseases", 
                "Ischemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "To assess the safety and efficacy of Adipose-Derived Regenerative Cells (ADRCs) delivered\n      via an intramyocardial route in the treatment of chronic ischemic heart disease in patients\n      who are not eligible for percutaneous or surgical revascularization."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Males or females > 20 and < 80 years of age\n\n          2. Significant multi-vessel coronary artery disease not amenable to percutaneous or\n             surgical revascularization\n\n          3. CCS Angina Functional Class II-IV and/or NYHA Stages of Heart Failure Class II or III\n\n          4. On maximal medical therapy for anginal symptoms and/or heart failure symptoms\n\n          5. Hemodynamic stability (SBP \u2265 90 mm/Hg, HR <110)\n\n          6. Ejection fraction \u2265 20% and \u2264 45%\n\n          7. Inducible ischemia using an objective assessment of ischemia within 1 year of\n             screening (i.e. exercise ECG changes, SPECT)\n\n          8. Left ventricular wall thickness \u2265 8 mm at the target site for cell injection\n\n        Exclusion Criteria:\n\n          1. Atrial fibrillation or flutter without a pace maker that guarantees a stable heart\n             rate\n\n          2. Unstable angina\n\n          3. LV thrombus, as documented by echocardiography\n\n          4. Planned staged treatment of CAD or other intervention on the heart\n\n          5. Platelet count < 100,000/mm3\n\n          6. WBC < 2,000/mm3\n\n          7. TIA or stroke within 90 days prior to randomization\n\n          8. ICD shock within 30 days prior to randomization\n\n          9. Any condition requiring immunosuppressive medication\n\n         10. A high-risk acute coronary syndrome (ACS) or a myocardial infarction in the 60 days\n             prior to randomization\n\n         11. Revascularization within 60 days prior to randomization\n\n         12. Inability to walk on a treadmill except for class IV angina patients who will be\n             evaluated separately\n\n         13. Hepatic dysfunction, as defined as aspartate aminotransferase (AST) and/or alanine\n             aminotransferase (ALT) > 1.5 times the upper limit of normal range (x ULN)\n\n         14. Hemoglobin \u2264 10.0 g/dL"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 30, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02052427", 
            "org_study_id": "ATHENA II"
        }, 
        "intervention": [
            {
                "arm_group_label": "Adipose-Derived Regenerative Cells (ADRCs) - Celution System", 
                "description": "ADRCs processed by the Celution System for reintroduction into the myocardium", 
                "intervention_name": "Adipose-Derived Regenerative Cells (ADRCs) - Celution System", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Placebo - Physiological Solution", 
                "description": "Physiological solution made of Lactated Ringers solution and a small amount (<1mL) of autologous blood", 
                "intervention_name": "Placebo - Physiological Solution", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Ischemic heart disease", 
            "Coronary artery disease", 
            "Chronic Heart Failure", 
            "Cardiovascular disease", 
            "adult stem cells", 
            "adipose derived regenerative cells"
        ], 
        "lastchanged_date": "January 30, 2014", 
        "location": {
            "contact": {
                "last_name": "Stacey Mazzurco, RN, BSN"
            }, 
            "facility": {
                "address": {
                    "city": "Cleveland", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "11100"
                }, 
                "name": "University Hospital Case Medical Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Adipose-derived Regenerative Cells in the Treatment of Patients With Chronic Ischemic Heart Disease Not Amenable to Surgical or Interventional Revascularization II", 
        "other_outcome": [
            {
                "measure": "Safety - Number of Patients Experiencing Treatment Emergent SAEs", 
                "safety_issue": "Yes", 
                "time_frame": "Treatment through 12 months"
            }, 
            {
                "measure": "Safety - Number of Patients Experiencing Arrhythmias Assessed via Holter monitor", 
                "safety_issue": "Yes", 
                "time_frame": "Screening through 3 months post treatment"
            }, 
            {
                "description": "Number of patients that experience a Major Adverse Cardiac Event (MACE)", 
                "measure": "Safety - Number of patients that experience a MACE", 
                "safety_issue": "Yes", 
                "time_frame": "Treatment through 12 months"
            }
        ], 
        "overall_contact": {
            "email": "etaylor@cytori.com", 
            "last_name": "Eve Taylor, PhD", 
            "phone": "858.458.0900", 
            "phone_ext": "5239"
        }, 
        "overall_contact_backup": {
            "email": "rdabkowski@cytori.com", 
            "last_name": "Rhiannon Dabkowski, BS", 
            "phone": "858-458-0900", 
            "phone_ext": "5297"
        }, 
        "overall_official": [
            {
                "affiliation": "The Stem Cell Center at Texas Heart Institute", 
                "last_name": "Emerson C. Perin, MD, PhD, FACC", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Cedars-Sinai Medical Center", 
                "last_name": "Timothy Henry, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change in Minnesota Living with Heart Failure Questionnaire prior to treatment and at 6 months post treatment.", 
            "measure": "Primary Efficacy - Change in Minnesota Living with Heart Failure Questionnaire", 
            "safety_issue": "No", 
            "time_frame": "6 months post treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02052427"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change in mVO2 at 6 months as assessed by Exercise Tolerance Test", 
                "measure": "Secondary Efficacy - Change in mVO2", 
                "safety_issue": "No", 
                "time_frame": "6 months post treatment"
            }, 
            {
                "description": "Change in LVESV/LVEDV at 6 months as assessed by Echocardiography", 
                "measure": "Secondary Efficacy - Change in LVESV/LVEDV", 
                "safety_issue": "No", 
                "time_frame": "6 months post treatment"
            }, 
            {
                "description": "Change in Ejection Fraction (%) at 6 months assessed by 2D Contrast Echocardiography", 
                "measure": "Secondary Efficacy - Change in Ejection Fraction", 
                "safety_issue": "No", 
                "time_frame": "6 months post treatment"
            }, 
            {
                "description": "Change in perfusion defect at 6 months assessed by Rest/Pharmacologic Stress SPECT", 
                "measure": "Secondary Efficacy - Change in perfusion defect", 
                "safety_issue": "No", 
                "time_frame": "6 months post treatment"
            }, 
            {
                "description": "Resource utilization - hospital length of stay, re-hospitalization for cardiac related events", 
                "measure": "Secondary Efficacy - Resource Utilization", 
                "safety_issue": "No", 
                "time_frame": "through 12 months post treatment"
            }, 
            {
                "description": "Change in heart failure symptoms, angina, and quality of life assessed by - NYHA classification, CCS classification, MLHFQ (other than 6 months)", 
                "measure": "Secondary Efficacy - Change in heart failure symptoms, angina, and quality of life", 
                "safety_issue": "No", 
                "time_frame": "through 12 months post treatment"
            }
        ], 
        "source": "Cytori Therapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cytori Therapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}